CRI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Carter's Inc (CRI) is not a clear buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has some constructive signs, including bullish moving averages and improving analyst sentiment, but momentum is mixed and the latest technicals do not show a strong entry setup. Given the lack of a proprietary buy signal, no recent news catalyst, and no fresh financial quarter data to confirm accelerating fundamentals, the better call is to hold and wait for either a cleaner technical breakout or more evidence that the turnaround is sticking.
CRI is trading at 40.65, essentially right around short-term support (S1 40.677) and below the pivot at 42.218. The moving averages remain bullish with SMA_5 > SMA_20 > SMA_200, which suggests the longer-term trend is still intact. However, MACD histogram is -0.306 and negatively expanding, showing weakening near-term momentum. RSI_6 at 35.527 is neutral-to-weak, not oversold enough to signal a strong buy. Overall, the chart is mixed: long-term trend is supportive, but current momentum is not strong enough to justify an aggressive immediate buy.
Analyst sentiment has improved meaningfully over the past few months. Goldman Sachs upgraded the stock to Neutral from Sell, UBS raised its price target to $41, and Wells Fargo most recently upgraded it to Equal Weight from Underweight with a higher $42 target, citing improved leadership, direct-to-consumer growth, and tariff upside. Wells also sees the upcoming fiscal Q2 results as a potential positive catalyst. Options data also leans bullish.
There is no recent news in the last week, so there is no fresh event-driven catalyst in the market right now. The technical setup is not strongly bullish because MACD momentum is weakening and price is sitting near support rather than breaking out. Hedge funds and insiders are both neutral, and there is no recent congress or influential figure trading activity to reinforce conviction. The market also appears to be waiting for proof that the CEO transition and strategic changes will translate into durable growth.
No usable latest-quarter financial snapshot was provided, so there is not enough data to assess the most recent quarter's revenue, earnings, or margin trends. Based on analyst commentary, Carter's recently posted a strong first quarter with improving business momentum, and the new fiscal Q2 is expected to matter for confirming whether growth is sustainable. The latest quarter season referenced in analyst notes is fiscal Q1, but detailed financials were not available here.
Analyst sentiment has turned more constructive. Goldman Sachs upgraded CRI to Neutral from Sell with a $38 target, UBS raised its target to $41 while keeping Neutral, and Wells Fargo recently upgraded the stock to Equal Weight from Underweight with a $42 target. The overall Wall Street view has shifted from bearish to more balanced, with pros focusing on leadership improvement, DTC growth, and tariff benefits. The remaining cons are uncertainty around CEO transition, input cost pressure, and limited long-term growth potential.
